ACTU · Company research
Actuate Therapeutics, Inc. Common stock (ACTU): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan | At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - Intraday Profile - siam.in | Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - Intraday Profile siam.in | View source ↗ | siam.in | Sep 10, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - Smart Money Flow Stocks - dars.gov.et | Actuate Therapeutics (ACTU) Falls 6.35% to $1.18 as Shares Test Lower Support - Smart Money Flow Stocks dars.gov.et | View source ↗ | dars.gov.et | Sep 10, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics (NasdaqGM:ACTU) Stock Forecast & Analyst Predictions - Simply Wall Street | Actuate Therapeutics (NasdaqGM:ACTU) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 4, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics, Inc. (ACTU) Stock Price & News - Syfe | Actuate Therapeutics, Inc. (ACTU) Stock Price & News Syfe | View source ↗ | Syfe | Aug 29, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics stock gets FDA clearance for elraglusib trial - Investing.com | Actuate Therapeutics stock gets FDA clearance for elraglusib trial Investing.com | View source ↗ | Investing.com | Aug 18, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView | Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard TradingView | View source ↗ | TradingView | Jul 17, 2026 | neutral | 0 | 0.6 |
| ACTU Forecast — Price Target — Prediction for 2027 - TradingView | ACTU Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors - GlobeNewswire | Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors GlobeNewswire | View source ↗ | GlobeNewswire | May 6, 2026 | neutral | 0 | 0.6 |
| NEWSLETTER: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - Reuters | NEWSLETTER: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial Reuters | View source ↗ | Reuters | Apr 22, 2026 | neutral | 0 | 0.6 |
| $ACTU stock is up 31% today. Here's what we see in our data. - Quiver Quantitative | $ACTU stock is up 31% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 20, 2026 | neutral | 0 | 0.6 |
| Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Benzinga | Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? Benzinga | View source ↗ | Benzinga | Apr 16, 2026 | neutral | 0 | 0.6 |
| Actuate Therapeutics, Inc. Common stock (ACTU) Stock Price, News, Quote & History - Yahoo! Finance Canada | Actuate Therapeutics, Inc. Common stock (ACTU) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Jan 16, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jun 26, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.